Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Unknown 4Completed 2Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Hepatocellular 20Nasopharyngeal Carcinoma 12Triple Negative Breast Neoplasms 11Esophageal Neoplasms 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Hodgkin Disease 5Recurrence 4Colorectal Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3NSCLC 3Advanced Gastric Cancer 3Respiratory Tract Diseases 2Rectal Neoplasms 2Osteosarcoma 2Neoplasms 2Nasopharyngeal Neoplasms 2Metastatic Gastric Adenocarcinoma 2Lymphoma, Extranodal NK-T-Cell 2Lung Diseases 2

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 12Rituximab 10Gemcitabine 9Paclitaxel 8Bendamustine Hydrochloride 8Lenalidomide 7Decitabine 7Cytarabine 7Carboplatin 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Bevacizumab 4Antilymphocyte Serum 4venetoclax 3pomalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Recurrence × camrelizumab × Clear all
NCT05320081 2022-04-11

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Huazhong University of Science and Technology

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Recurrence

NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Sun Yat-sen University

Phase 1/2 Unknown
33 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT03914352 2019-04-16

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Cancer Hospital of Guangxi Medical University

Phase NA Unknown
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT03250962 2019-04-01

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Chinese PLA General Hospital

Phase 2 Unknown
280 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡